Cell cycle: repurposing MYC and E2F in the absence of RB.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Establishment and rescue of fibroblast cell lines carrying a nonsense mutation of RB1 by CRISPR-based base editing.Scientific reports · 2025
   Article
2. Expression of Wnt signaling proteins LEF1, β-catenin, GSK3β, DVL1, and N-myc varies across retinoblastoma subtypes and pRb phosphorylation status.Scientific reports · 2024
   Article
3. Retinoblastoma Protein Is Required for Epstein-Barr Virus Replication in Differentiated Epithelia.Journal of virology · 2023
   Article
4. Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC.Cell chemical biology · 2021
   Article
5. AFrontiers in genetics · 2021
   Article
6. Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma.Cancer medicine · 2017
   Article

Corrections and comments

• Comment on
  Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as